Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) regarding their holdings in American Depositary Shares (ADSs).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The filing details increases in ADS holdings for specific directors and connected persons resulting from the re-investment of dividends paid on April 11, 2013. The transactions occurred at a price of $48.36 per ADS. No other material changes to the company's operations or financial position are reported in this text.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It strictly adheres to Disclosure and Transparency Rules 3.1.4R(1)(a) and (c) regarding the notification of director transactions.
Key Facts for Investor Verification
- Transaction Date: April 11, 2013.
- Transaction Price: $48.36 per ADS.
- Transaction Type: Dividend re-investment leading to increased holdings.
- Directors Involved: Dr M M Slaoui, Mrs D P Connelly, Mr W C Louv, and Mr D E Troy.
- Connected Person: Dr K Slaoui (connected to Dr M M Slaoui).
- Notification Date: The Company was advised on April 18, 2013; the report was signed on April 19, 2013.